Definium Therapeutics is trading at $39.34, down 4.00%, amid broad risk-off pressure linked to renewed U.S.-Iran tensions, higher oil prices, and increased expectations for a Federal Reserve rate hike.
- Reuters reported that U.S. indexes declined as geopolitical developments and Kevin Warsh’s hawkish remarks intensified inflation concerns.
- No clear negative company-specific catalyst was identified; Stifel reiterated Buy and maintained a $60 price target on August 31, 2026.